Can a lower dose of Alzheimer's drug work just as well?

NCT ID NCT07505095

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test whether a lower dose of the drug lecanemab works as well as the standard dose for people with early Alzheimer's disease. Researchers will compare brain scans, memory tests, and blood markers in 140 participants over 18 months. The goal is to find the most effective dose with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lecanemab
What this could lead to: If successful, this could show that a lower dose of lecanemab is just as effective, potentially reducing side effects and treatment costs for early Alzheimer's patients.
What could go wrong: This is a small, early-stage study (140 people) comparing doses, not a large trial. The lower dose may prove less effective, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DEMENTIA ALZHEIMER DISEASE (AD) MCI-AD, EARLY STAGE ALZHEIMER'S DISEASE

Contacts and locations

Locations

Human Subject Research Ethics Committee, 2ndAffiliated Hospital, School of Medicine, Zhejiang University,

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.